All In MedTech

Device Trial Radar · NCT05245851

Clinical Deployment and Validation of Rho

Clinical Deployment and Validation of Rho - An Opportunistic Osteoporosis Screening Software-as-a-Medical Device

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,146

Actual

Start

Nov 21, 2022

Primary completion

Oct 1, 2023

Study completion Oct 1, 2023

Sponsor

Lead sponsor
16 Bit Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Amgen; Sunnybrook Health Sciences Centre
First posted
Feb 18, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated device
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed software, called RhoTM, that analyzes various x-rays, performed in patient age 50 and above for any clinical indication, to identify patients with low BMD. RhoTM is intended to function as a pre-screening device for low BMD. This study seeks to assess the clinical performance and impact of implementing RhoTM in real-world settings by analyzing its performance and impact on DXA referrals.

Conditions

  • Low Bone Density

Interventions

  • Opportunistic screening for low BMDDevice

    Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements: * This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD). * This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate. The radiologist can choose to include this as an incidental finding in their report to the referring physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive predictive valueTime frame: 9 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Holland Orthopaedic & Arthritic Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.